The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“With the prospect of SIGNIFICANT further non-dilutive cash inflows from our partners”
Hopefully a very blue day at the very least!!
Definitely 10p+ incoming!
In the meantime, we are also focussing on our new and significant partnership with Stalicla SA and are driving our breast cancer programme forward in collaboration with the Manchester Breast Centre. We continue to explore partnering opportunities in the context of a considerably longer cash runway, with the prospect of significant further non-dilutive cash inflows from our partners."
Great RNS.
Supporting an ISS in GBM for the first clinical phase will result in the Company having financial resources for a further year; at least to the end of Q4 2024. This runway will extend well into 2025 if further milestones relating to the results from the HV study and FDA IND approval are received following the Stalicla SA licensing transaction announced this week. Previous guidance issued was for a much shorter financial runway to Q4 2023.
"In the meantime, we are also focussing on our new and significant partnership with Stalicla SA and are driving our breast cancer programme forward in collaboration with the Manchester Breast Centre. We continue to explore partnering opportunities in the context of a considerably longer cash runway, with the prospect of significant further non-dilutive cash inflows from our partners."
Katstrangler…. You were saying ;)
Every spike in the share price has only been temporary and a selling opportunity. Could this time be different, probably not. This company has promised so much over the years and delivered nothing all to the detriment of the shareholders. If it's product actually had any medical use it would have been fully exploited by now. It's like a series finale, gives you just enough to keep you hooked and wanting more but the story line doesn't change, occasional price spikes and the eventual pull back to lower levels. All the while the bods don't touch these with a barge pole but are more than happy to extract their extortionate renumeration packages.
rns' don't come before presentations... they come when there's news of a buyer or seller completing their trades. no reason for it to appear before presentation. be nice if it did, though.
today was disappointing. don't let anyone tell you otherwise. the rise just wasn't big enough to warrant such a reversal. but having happened, one would have to ask why would it bounce tomorrow? i'm hoping the presentation will restate the upside and create another feeding frenzy but don't be surprised if it doesn't. markets are all over the place atm.
It can’t be ruled out !
Yep , probably a Tr-1. :-)
£1.3M of shares traded today. Shows there’s a market both ways. Doubt the likes of AXA will want to lose their holding on the share though and could possibly increase themselves given the award update.
Won't have to wait 6 months. It'll recover tomorrow. Was always going to fall after such a big one day rise. I am away for a couple of days so wanted to get in before the presentation tomorrow. We'll soon see a bounce back.
Whats the likelyhood of an RNS before the presentaton tomorrow....
On very low Volume, from 6p to 5.6 on 300K shares…..MM’s playing peeps here,
Was thinking of buying into this first thing this morning but just didn't like the gap up at opening, glad I waited
Will keep my powder dry for a lower entry point may miss the chance to get these altogether but at least I'll be able to sleep comfortably at night (or even day - depending where I'm working)
News yesterday was unbelievably good, so need to buy and hold until next year (or longer)
Will be interesting to see the end of day share consolidation and if we have any large trades processed ahead of tomorrows presentation :)
So much for your 8p Watching2?
I might get my predicted buy in before 4.30pm to start with a 5 - stranger things have happened on AIM.
LOL.
GLA.
Still doing it. Bought £3613 for 6.17p. Just now.
Just bought £5796 worth for 6.237p. Buys showing as sells.
We are in a bear market unfortunately.
Let’s see if we get that W figure and a blue finish
Whatever
Buyers getting their fill before the presentation tomorrow.
If it goes through, this link should take you straight there to register:
https://www.investormeetcompany.com/evgen-pharma-plc/register-investor